From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015–2025)

作者：Hanlin Liu, Yuqiang Fu, Jianwei Yang, Li Wang, Junsheng Bao, Li Ding, W. Shi, Siyu Chen, X.-H. Li · 发表于：Journal of Translational Medicine · 年份：2026 · DOI：10.1186/s12967-026-08043-y · 被引用次数：1 · 研究领域：Bladder and Urothelial Cancer Treatments、Renal cell carcinoma treatment、Urinary Tract Infections Management

BACKGROUND: Urine-based liquid biopsy enables non-invasive, repeat sampling in urologic cancers, yet evidence remains fragmented across diseases, analytes, and platforms. We mapped the research landscape and clinically framed thematic trajectories of the field. METHODS: English-language articles and reviews (2015–2025) were retrieved from WoSCC (SCIE) using urologic cancer terms combined with urine/urinary and “liquid biopsy”. CiteSpace, VOSviewer and bibliometrix were used to map collaboration, co-citation, citation bursts and keyword evolution. Robustness was assessed via sensitivity analyses and matched PubMed validation. RESULTS: Among 431 publications from 51 countries, output rose steadily and accelerated in 2021. Co-citation and citation-burst analyses suggested a shift from feasibility-oriented method expansion to standardization-oriented, platform-integrative synthesis. Collaboration showed a Europe–North America core with growing East Asian participation. Keywords converged on two clinical streams: prostate cancer diagnostics (urinary RNA/exosome panels and multivariable models for biopsy decision-making) and urothelial cancer monitoring (mutation/methylation assays and enhanced cytology for surveillance and potential cystoscopy de-escalation). Evidence for renal cell carcinoma and rarer urologic cancers remained sparse and largely exploratory, including methylation profiling, extracellular vesicles (EVs) and metabolomics. CONCLUSIONS: This bibliometric evidence map...